MedTrace Logo

Analysis of a New Biomarker for Prostate Cancer Diagnosis

NCT01819740 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2013-03-28

No results posted yet for this study

Summary

The aim of our study is to determine if the levels of the "HEM" substance in seminal plasma are associated with the presence of prostate cancer in transrectal prostate biopsy.

Conditions

  • Patients With Suspected Prostate Cancer

Interventions

OTHER

determine the levels of the "HEM" substance in seminal plasma

Sponsors & Collaborators

  • Corporacion Parc Tauli

    lead OTHER

Principal Investigators

  • Miriam Barrio-Muñoz · Hospital Universitario Parc Tauli de Sabadell. Spain

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2013-04-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01819740 on ClinicalTrials.gov